Statement by Blue Earth Diagnostics on COVID-19 click here for more information

Latest News From Blue Earth Diagnostics


Blue Earth Diagnostics Announces Addition of Axumin® (fluciclovine (18F)) to EAU Guidelines for imaging in patients with biochemical recurrence in Prostate Cancer

Oxford, UK – April 16, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics…

Blue Earth Diagnostics celebrates five year anniversary

Oxford, UK – March 6, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics…

First production and administration of Axumin® (fluciclovine (18F)) in Italy.

Oxford, UK – February 12, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics…

First production and administration of Axumin® (fluciclovine (18F)) in France.

Oxford, UK – December 12, 2018 – Blue Earth Diagnostics, a leading molecular imaging diagnostics…

Blue Earth Diagnostics Announces Results of Investigational Phase 3 Blinded Image Evaluation Study of 18F-Fluciclovine PET Imaging in Glioma

– Presented at 23rd Annual Scientific Meeting of the Society for Neuro-Oncology – BURLINGTON, Mass.…

Blue Earth Diagnostics Announces 18F-Fluciclovine Research Presentation at Upcoming Society for Neuro-Oncology (SNO) Annual Scientific Meeting

BURLINGTON, Mass. and OXFORD, UK, November 14, 2018 – Blue Earth Diagnostics, a molecular imaging…

Blue Earth Diagnostics Announces Fluciclovine F 18 Research Presentations at Upcoming ASTRO Annual Meeting

BURLINGTON, Mass. and OXFORD, UK, October 17, 2018 – Blue Earth Diagnostics, a molecular imaging…

Blue Earth Diagnostics wins prestigious “Best Emerging Biotech” award

Oxford, UK – October 12, 2018 – Blue Earth Diagnostics, a leading molecular imaging diagnostics…

Axumin® (fluciclovine (18F)) receives positive recommendation from Transparency Committee of the French HAS, for use in PET imaging of suspected recurrent prostate cancer

Oxford, UK – October 2, 2018 – Blue Earth Diagnostics, a leading molecular imaging diagnostics…